Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 129 clinical trials
Exercise to Boost Response to Checkpoint Blockade Immunotherapy

30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles

vaccination
ipilimumab
immunomodulator
immunologic adjuvant
pembrolizumab
  • 0 views
  • 23 May, 2022
  • 1 location
High-Risk Skin Cancers With Atezolizumab Plus NT-I7

The purpose of this study is to test whether the addition of NT-I7 to atezolizumab provides clinically meaningful outcomes for patients with anti-PD-1/PD-L1 naive or relapsed/refractory high-risk melanoma, Merkel Cell Carcinoma (MCC) and cutaneous Squamous Cell Carcinoma (cSCC)

atezolizumab
BRAF
skin cancer
metastatic melanoma
squamous cell carcinoma
  • 14 views
  • 26 Feb, 2022
  • 7 locations
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma (I-MAT)

The I-MAT trial is a randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as adjuvant immunotherapy.

18f-fdg
carcinoma
immunomodulator
positron emission tomography
avelumab
  • 1 views
  • 03 Jun, 2022
  • 17 locations
Personalized PRRT of Neuroendocrine Tumors (P-PRRT)

In this study, peptide receptor radionuclide therapy (PRRT) with 177Lu-Octreotate (LuTate) will be personalized, i.e. administered activity of LuTate will be tailored for each patient to maximize absorbed radiation dose to tumor, while limiting that to healthy organs. The purpose of this study is to: Assess the objective (radiological), symptomatic …

somatostatin
177lu-octreotate
pet scan
neuroendocrine tumor
positron emission tomography
  • 91 views
  • 23 Feb, 2022
  • 1 location
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

This is a first-in-human (FIH), Phase 1, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors.

cytotoxic drug
squamous cell carcinoma
small molecule
ejection fraction
EGFR
  • 0 views
  • 25 May, 2022
  • 1 location
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase …

serum bilirubin
somatostatin
neuroendocrine tumor
small molecule
cancer
  • 49 views
  • 03 Feb, 2022
  • 7 locations
CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer

CMP-001-009 is a Phase 2 study of intratumoral CMP-001 in combination with an intravenous PD-1-blocking antibody administered to participants with certain types of advanced or metatastic cancer. The primary objective of the study is to determine the Investigator-assessed confirmed objective response with CMP-001 in combination with a programmed cell death …

cancer
  • 0 views
  • 28 Jul, 2022
  • 13 locations
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

This is a Phase 2, single center, open-label, single-arm study designed to evaluate the efficacy, safety, tolerability, and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic high grade neuroendocrine cervical cancer.

platelet count
brain metastases
heart failure
EGFR
chemotherapy regimen
  • 0 views
  • 16 May, 2022
  • 1 location
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.

pembrolizumab
cancer
nivolumab
nbtxr3
  • 13 views
  • 08 Jul, 2022
  • 7 locations
Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms (RAPNEN)

This study evaluates the possibility and the safety of performing local therapy for Pancreatic neuroendocrine neoplasms (PanNENs) using radiofrequency ablation of the tumor under ultrasonography (EUS) guidance.

fasting
pet-ct scan
insulin
fine needle biopsy
endoscopic ultrasound
  • 9 views
  • 23 Mar, 2022
  • 1 location